EC Approves First Teriparatide Biosimilar: What Zandoriah Means for Peptide Manufacturing

Executive Summary

The European Commission has approved CinnaGen’s Zandoriah (teriparatide biosimilar) for the treatment of osteoporosis in adults, marking a significant regulatory milestone for the peptide biosimilar market. Teriparatide — recombinant human parathyroid hormone (PTH 1–34), a 34-amino acid peptide — has been a mainstay anabolic osteoporosis therapy since Eli Lilly’s Forteo gained approval in 2002. The EC decision signals that peptide biosimilars are entering a new phase of regulatory maturity, with potentially far-reaching implications for manufacturing capacity, pricing dynamics, and CDMO strategy across the broader peptide therapeutics field.

Context

Teriparatide is a truncated form of parathyroid hormone — specifically the biologically active N-terminal 1–34 amino acid fragment of the 84-amino acid native hormone. Unlike antiresorptive agents (bisphosphonates, denosumab) that slow bone loss, teriparatide is anabolic: it stimulates new bone formation when administered intermittently. This mechanism makes it uniquely valuable for patients with severe osteoporosis who have already suffered fractures or failed other therapies.

Eli Lilly’s Forteo dominated the market for nearly two decades, generating peak annual sales of approximately $1.4 billion before losing US patent exclusivity in 2019. Since then, the terrain has shifted: the US FDA approved its first teriparatide biosimilar (from Alvogen/Teva) in 2023, and the EMA has now followed with CinnaGen’s Zandoriah receiving EC approval in June 2026. CinnaGen, an Iran-based biopharmaceutical company with a growing European regulatory footprint, positions this approval as a step toward expanding biosimilar access across the EU market.

The Data

Expert Insight

Anti-Pattern: Assuming peptide biosimilars follow the small-molecule generic playbook. The single most common mistake industry analysts make is treating peptide biosimilars as interchangeable with chemically synthesized generics. Teriparatide is a recombinant peptide produced in E. coli, not a chemically synthesized small molecule. Biosimilarity for peptides requires demonstrating comparability across primary sequence, higher-order structure, post-translational modifications, and biological activity — a burden that sits between small-molecule generics and monoclonal antibody biosimilars in complexity.

Experienced peptide developers know that E. coli expression of the 34-amino acid PTH fragment is deceptively challenging. The peptide is prone to methionine oxidation (Met8, Met18), deamidation (Asn10, Asn16), and aggregation at formulation concentrations. A teriparatide biosimilar manufacturer must replicate not just the amino acid sequence but also the impurity profile, aggregation kinetics, and delivery device performance of the originator. The EC’s approval of Zandoriah confirms that CinnaGen has navigated these hurdles — but it also serves as a reminder that the analytical and CMC burden for peptide biosimilars is substantial and often underestimated by teams coming from a small-molecule background.

What Experienced Teams Know: The real manufacturing bottleneck for teriparatide biosimilars is not the fermentation step but downstream purification. The 34-mer peptide requires multiple chromatography steps (typically ion-exchange followed by reversed-phase HPLC) to achieve pharmaceutical-grade purity, and HPLC capacity remains the rate-limiting factor across the broader peptide CDMO landscape. With semaglutide and tirzepatide consuming vast amounts of preparative HPLC capacity worldwide, teriparatide biosimilar manufacturers face direct competition for purification slots — a dynamic that influences both cost of goods and time-to-market for every new peptide biosimilar entrant.

Frequently Asked Questions

What is teriparatide and how does it differ from other osteoporosis drugs?

Teriparatide is a recombinant fragment of human parathyroid hormone (amino acids 1–34) that stimulates new bone formation. Unlike bisphosphonates or denosumab, which work by slowing bone resorption, teriparatide is an anabolic agent — it builds bone. This makes it particularly valuable for patients with severe osteoporosis who have already suffered fractures. The standard course is 24 months of daily subcutaneous injection.

Why is the EC approval of a teriparatide biosimilar significant for the broader peptide field?

This approval establishes a regulatory precedent for recombinant peptide biosimilars in Europe, following the earlier US precedent in 2023. It signals to manufacturers and investors that regulatory pathways for peptide biosimilars are maturing. As more peptide drugs — particularly GLP-1 receptor agonists like semaglutide — approach patent expiration, the teriparatide biosimilar pathway serves as a template for what comparable peptide products will face in terms of analytical, preclinical, and clinical data requirements.

What does this mean for the peptide CDMO and manufacturing landscape?

Every new peptide biosimilar approval adds incremental demand to an already capacity-constrained peptide manufacturing ecosystem. Teriparatide (4.1 kDa, 34 amino acids) is smaller than GLP-1 agonists like semaglutide, meaning it competes for different segments of manufacturing capacity — primarily small-to-medium peptide synthesis and purification lines. However, competition for HPLC purification capacity and lyophilization suites affects all peptide programs, large and small. CDMOs with flexible, multi-scale capabilities will be best positioned to capture teriparatide biosimilar manufacturing contracts.

Further Reading

• The Race to Biosimilar Semaglutide: Who’s Ahead and What It Means for Price
• FDA and EMA Peptide Drug Approvals: A 2020–2026 Regulatory Analysis
• The Economics of Peptide API Manufacturing: A Cost Breakdown

Last reviewed: June 2026. Peptide Proof Editorial Team. Source: FiercePharma — European Commission Approves CinnaGen’s Zandoriah (Teriparatide Biosimilar); Eli Lilly SEC filings; EMA public assessment reports.